InvestSMART

PYC Therapeutics Limited (ASX: PYC) - Announcements

Current share price for PYC : $2.490 0.08 (3.11%)+

ASX company news and announcements for PYC Therapeutics Limited (PYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PYC Therapeutics Limited (PYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PYC Therapeutics Limited (PYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PYC Therapeutics Limited (PYC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,449 PKD Program - Presentation of Safety Data at ANZSN 29 Aug 2025 8:37AM $1.290 $2.490 risen by 93.02%
$2,449 2025 Corporate Governance Statement 28 Aug 2025 5:24PM $1.290 $2.490 risen by 93.02%
$2,449 Appendix 4G 28 Aug 2025 5:22PM $1.290 $2.490 risen by 93.02%
$2,449 2025 Annual Report to Shareholders 28 Aug 2025 5:18PM $1.290 $2.490 risen by 93.02%
$2,449 Appendix 4E 28 Aug 2025 5:15PM $1.290 $2.490 risen by 93.02%
$2,449 Approval to Escalate Dosing in Kidney Disease Clinical Trial 8 Aug 2025 8:59AM $1.245 $2.490 risen by 100%
$2,449 Q3 2025 Investor Webinar Presentation 1 Aug 2025 8:34AM $1.240 $2.490 risen by 100.81%
$2,449 Q3 Investor Webinar 1 August 2025 28 Jul 2025 8:59AM $1.295 $2.490 risen by 92.28%
$2,449 Quarterly Activities/Appendix 4C Cash Flow Report 21 Jul 2025 8:42AM $1.360 $2.490 risen by 83.09%
$2,449 Approval to Progress Kidney Disease Trial to Next Stage 7 Jul 2025 8:57AM $1.280 $2.490 risen by 94.53%
$2,449 Fourth Drug Program Progressing to Human Trials 27 Jun 2025 9:11AM $1.265 $2.490 risen by 96.84%
$2,449 FDA Alignment on Registrational Trial Design RP11 Program 23 Jun 2025 8:57AM $1.150 $2.490 risen by 116.52%
$2,449 SRC Approves Dose Escalation in ADOA Clinical Trial 11 Jun 2025 9:17AM $1.205 $2.490 risen by 106.64%
$2,449 Investor Webinar Presentation 30 May 2025 8:59AM $1.200 $2.490 risen by 107.50%
$2,449 Approval to Escalate Dosing in Kidney Disease Trial 26 May 2025 9:13AM $1.200 $2.490 risen by 107.50%
$2,449 Notification of cessation of securities - PYC 23 May 2025 4:29PM $1.200 $2.490 risen by 107.50%
$2,449 Q2 Investor Webinar 30 May 2025 13 May 2025 9:32AM $1.230 $2.490 risen by 102.44%
$2,449 Foundation Fighting Blindness Presentation Materials 2 May 2025 8:31AM $1.240 $2.490 risen by 100.81%
$2,449 Change in substantial holding 28 Apr 2025 4:33PM $1.200 $2.490 risen by 107.50%
$2,449 Presentation of Clinical Proof of Concept in Lead Program 28 Apr 2025 9:02AM $1.115 $2.490 risen by 123.32%
$2,449 Quarterly Activities/Appendix 4C Cash Flow Report 24 Apr 2025 8:48AM $1.030 $2.490 risen by 141.75%
$2,449 Application for quotation of securities - PYC 23 Apr 2025 5:44PM $1.030 $2.490 risen by 141.75%
$2,449 Completion of Entitlement Offer 17 Apr 2025 8:35AM $1.055 $2.490 risen by 136.02%
$2,449 First Subject Dosed in PKD Clinical Trial 10 Apr 2025 8:45AM $0.995 $2.490 risen by 150.25%
$2,449 Placement of Shortfall 9 Apr 2025 9:45AM $1.055 $2.490 risen by 136.02%

101 - 125 of 942 results

Page 5 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.